Lest we forget: https://nwbio.com/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board/ Just three months b/4 DCVax-l MAA filed (And five months before DCvax-l MAA validation (aka: start of clock on review) by MHRA, and, coincidently, Survaxm 2b trial with potentially relevant control arm reaching full enrollment.)